Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to apoe genotype

Current Alzheimer Research

Volumn 11, Issue 8, 2014, Pages 773-784

  Albert, Marilyn ^a   Soldan, Anja ^a   Gottesman, Rebecca ^a   McKhann, Guy ^a   Sacktor, Ned ^a   Farrington, Leonie ^a   Grega, Maura ^a   Turner, Raymond ^a   Lu, Yi ^a   Li, Shanshan ^a   Wang, Mei Cheng ^a   Selnes, Ola ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein E genotype; Cognitive decline; Episodic memory; Longitudinal follow up; Mild cognitive impairment; Preclinical alzheimer s disease

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ARTICLE; ASSOCIATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONSENSUS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; MENTAL PERFORMANCE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MOLECULAR PHYLOGENY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SYMPTOM; ALZHEIMER DISEASE; COMPLICATION; DISEASE COURSE; GENETICS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TIME FACTOR;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84926167473     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501108140910121920     Document Type: Article

References (70)

1. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychologicalchanges in "normal" aging: evidence for preclinical Alzheimer diseasein cognitively normal individuals. J Neuropathol Exp Neurol57: 1168-1174 (1998)
2. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. JNeuropathol Exp Neurol 62: 1087-1095 (2003)
3. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitiveimpairment from two community-based studies. Neurology 66:1837-1844 (2006)
4. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathologyin cognitively normal aging. Ann Neurol 67: 122-131(2010)
5. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkersand Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275-1283 (2010)
6. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillaramyloid-beta burden in cognitively normal people at 3 levels ofgenetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A106: 6820-6825 (2009)
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer'sdisease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines forAlzheimer's disease. Alzheimers Dement 7: 280-292 (2011)
8. Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, et al. Neuropsychological measures in normal individuals thatpredict subsequent cognitive decline. Arch Neurol 64: 862-871(2007)
9. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, et al. Brain structural alterations before mild cognitiveimpairment. Neurology 68: 1268-1273 (2007)
10. Rubin EH, Storandt M, Miller JP, Kinscherf DA, Grant EA, Morris JC, et al. A prospective study of cognitive function and onset ofdementia in cognitively healthy elders. Arch Neurol 55: 395-401(1998)
11. Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Jr., Xiong C, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia:a clinicopathologic study. Arch Neurol 62: 758-765 (2005)
12. Howieson DB, Carlson NE, Moore MM, Wasserman D, Abendroth CD, Payne-Murphy J, et al. Trajectory of mild cognitive impairmentonset. J Int Neuropsychol Soc 14: 192-198 (2008)
13. De Santi S, Pirraglia E, Barr W, Babb J, Williams S, Rogers K, et al. Robust and conventional neuropsychological norms: diagnosisand prediction of age-related cognitive decline. Neuropsychology 22: 469-484 (2008)
14. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal studyof the transition from healthy aging to Alzheimer disease. ArchNeurol 66: 1254-1259 (2009)
15. Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive declinein prodromal Alzheimer disease and mild cognitive impairment.Arch Neurol 68: 351-356 (2011)
16. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the associationbetween apolipoprotein E genotype and Alzheimer disease. Ameta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349-1356 (1997)
17. Levy JA, Bergeson J, Putnam K, Rosen V, Cohen R, Lalonde F, etal. Context-specific memory and apolipoprotein E (ApoE) epsilon4: cognitive evidence from the NIMH prospective study of risk forAlzheimer's disease. J Int Neuropsychol Soc 10: 362-370 (2004)
18. Rosen VM, Sunderland T, Levy J, Harwell A, McGee L, Hammond C, et al. Apolipoprotein E and category fluency: evidencefor reduced semantic access in healthy normal controls atrisk for developing Alzheimer's disease. Neuropsychologia 43:647-658 (2005)
19. Greenwood PM, Lambert C, Sunderland T, Parasuraman R. Effects of apolipoprotein E genotype on spatial attention, working memory,and their interaction in healthy, middle-aged adults: resultsFrom the National Institute of Mental Health's BIOCARD study. Neuropsychology 19: 199-211 (2005)
20. Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, et al. Longitudinal changes in cognition and behavior inasymptomatic carriers of the APOE e4 allele. Neurology 62: 1990-1995 (2004)
21. Jorm AF, Mather KA, Butterworth P, Anstey KJ, Christensen H, Easteal S. APOE genotype and cognitive functioning in a largeage-stratified population sample. Neuropsychology 21: 1-8 (2007)
22. Sager MA, Hermann B, La Rue A. Middle-aged children of personswith Alzheimer's disease: APOE genotypes and cognitivefunction in the Wisconsin Registry for Alzheimer's Prevention. JGeriatr Psychiatry Neurol 18: 245-249 (2005)
23. Chen JG, Edwards CL, Vidyarthi S, Pitchumoni S, Tabrizi S, Barboriak D, et al. Learning and recall in subjects at genetic risk forAlzheimer's disease. J Neuropsychiatry Clin Neurosci 14: 58-63(2002)
24. Caselli RJ, Dueck AC, Locke DE, Hoffman-Snyder CR, Woodruff BK, Rapcsak SZ, et al. Longitudinal modeling of frontal cognitionin APOE epsilon4 homozygotes, heterozygotes, and noncarriers. Neurology 76: 1383-1388 (2011)
25. Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, et al. Stronger effect of amyloid load than APOE genotype on cognitivedecline in healthy older adults. Neurology 79: 1645-1652(2012)
26. Jochemsen HM, Muller M, van der Graaf Y, Geerlings MI. APOEepsilon4 differentially influences change in memory performancedepending on age. The SMART-MR study. Neurobiol Aging 33:832 e815-822 (2012)
27. Mayeux R, Small SA, Tang M, Tycko B, Stern Y. Memory performancein healthy elderly without Alzheimer's disease: effects oftime and apolipoprotein-E. Neurobiol Aging 22: 683-689 (2001)
28. Wechsler D. Wechsler Memory Scale - Revised Manual. San Antonio,TX: Psychological Corporation, 1987
29. Delis DC, Kramer JH, Kaplan E, Ober BA. California VerbalLearning Test. San Antonio, TX: The Psychological Corporation,1987
30. Rey A. L’examen psychologique dans les cas d’encephalopathietraumatique. Archives de Psychologie 28: 286-340 (1941)
31. Reitan RM. Validity of the trail making test as an indicator of organicbrain damage. Perceptual and Motor Skills 8: 271-276(1958)
32. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia:Lee & Febiger, 1983
33. Benton AL, Hamsher KS. Multilingual Aphasia Examination. IowaCity: University of Iowa Press, 1976
34. Wechsler D. Wechsler Adult Intelligence Scale - Revised Manual. New York: The Psychological Corporation, 1981
35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". Apractical method for grading the cognitive state of patients for theclinician. J Psychiatr Res 12: 189-198 (1975)
36. Klove H. Grooved Pegboard. Lafayette, IN, 1963
37. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensiveassessment of psychopathology in dementia. Neurology 44: 2308-2314 (1994)
38. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, etal. Development and validation of a geriatric depression screeningscale: a preliminary report. J Psychiatr Res 17: 37-49 (1982)
39. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A newclinical scale for the staging of dementia. Br J Psychiatry 140: 566-572 (1982)
40. Morris JC. The Clinical Dementia Rating (CDR): current versionand scoring rules. Neurology 43: 2412-2414 (1993)
41. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardizedclinical information. Arch Neurol 57: 675-680 (2000)
42. Petersen RC. Mild cognitive impairment as a diagnostic entity. JIntern Med 256: 183-194 (2004)
43. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer'sdisease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines forAlzheimer's disease. Alzheimers Dement 7: 263-269 (2011)
44. Kalbfleisch J, Prentice R. Statistical Analysis of Failure Time Data. Hoboken, NJ: Wiley & Sons, 2002
45. Hosmer D, Lemeshow S, May S. Applied Survival Analysis.Hoboken, NJ: Wiley & Sons, 2008
46. Wang MC, Brookmeyer R, Jewell NP. Statistical models for prevalentcohort data. Biometrics 49: 1-11 (1993)
47. Tibshirani R. Regression shrinkage and selection via the Lasso. Journal of the Royal Statistical Society Series B-Methodologica l58: 267-288 (1996)
48. Tibshirani R. The lasso method for variable selection in the coxmodel. Statistics in Medicine 16: 385-395 (1997)
49. Schneider LS, Lahiri DK. The perils of Alzheimer's drug development.Curr Alzheimer Res 6: 77-78 (2009)
50. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and Biomarker Changes in Dominantly InheritedAlzheimer's Disease. N Engl J Med: (2012)
51. Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR. Earlylife linguistic ability, late life cognitive function, and neuropathology:findings from the Nun Study. Neurobiol Aging 26: 341-347(2005)
52. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, et al. Visual memory predicts Alzheimer'sdisease more than a decade before diagnosis. Neurology 60: 1089-1093 (2003)
53. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB.The preclinical phase of alzheimer disease: A 22-year prospectivestudy of the Framingham Cohort. Arch Neurol 57: 808-813 (2000)
54. Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC,et al. Preclinical Alzheimer disease: neuropsychological test performance1.5 to 8 years prior to onset. Neurology 63: 2341-2347(2004)
55. Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychologicaltests accurately predict incident Alzheimer disease after 5 and 10years. Neurology 64: 1853-1859 (2005)
56. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, et al. Prodromal Alzheimer's disease: successiveemergence of the clinical symptoms. Ann Neurol 64: 492-498(2008)
57. Chey J, Kim JW, Cho HY. Effects of apolipoprotein E phenotypeson the neuropsychological functions of community-dwelling elderlyindividuals without dementia. Neurosci Lett 289: 230-234(2000)
58. Flory JD, Manuck SB, Ferrell RE, Ryan CM, Muldoon MF. Memoryperformance and the apolipoprotein E polymorphism in acommunity sample of middle-aged adults. Am J Med Genet 96:707-711 (2000)
59. Nilsson LG, Adolfsson R, Backman L, Cruts M, Nyberg L, Small BJ, et al. The influence of APOE status on episodic and semanticmemory: data from a population-based study. Neuropsychology 20:645-657 (2006)
60. Reed T, Carmelli D, Swan GE, Breitner JC, Welsh KA, Jarvik GP,et al. Lower cognitive performance in normal older adult maletwins carrying the apolipoprotein E epsilon 4 allele. Arch Neuro l51: 1189-1192 (1994)
61. Zehnder AE, Blasi S, Berres M, Monsch AU, Stahelin HB, Spiegel R. Impact of APOE status on cognitive maintenance in healthy elderlypersons. Int J Geriatr Psychiatry 24: 132-141 (2009)
62. Schiepers OJ, Harris SE, Gow AJ, Pattie A, Brett CE, Starr JM, etal. APOE E4 status predicts age-related cognitive decline in theninth decade: longitudinal follow-up of the Lothian Birth Cohort1921. Mol Psychiatry 17: 315-324 (2012)
63. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory declineand the APOE epsilon4 effect. N Engl J Med 361: 255-263(2009)
64. Wetter SR, Delis DC, Houston WS, Jacobson MW, Lansing A, Cobell K, et al. Deficits in inhibition and flexibility are associatedwith the APOE-E4 allele in nondemented older adults. J Clin ExpNeuropsychol 27: 943-952 (2005)
65. Miller MI, Younes L, Ratnanather JT, Brown T, Trinh H, Postell E, et al. The diffeomorphometry of temporal lobe structures in preclinicalAlzheimer's disease. Neuroimage Clin 3: 352-360 (2013)
66. Baldo JV, Arevalo A, Patterson JP, Dronkers NF. Grey and whitematter correlates of picture naming: evidence from a voxel-basedlesion analysis of the Boston Naming Test. Cortex; a journal devotedto the study of the nervous system and behavior 49: 658-667(2013)
67. Zhang H, Sachdev PS, Wen W, Kochan NA, Crawford JD, Brodaty H, et al. Grey matter correlates of three language tests in nondementedolder adults. PLoS One 8: e80215 (2013)
68. Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, et al. CSFbiomarker changes precede symptom onset of mild cognitive impairment. Neurology 81: 1753-1758 (2013)
69. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer'sdisease: an updated hypothetical model of dynamic biomarkers.Lancet Neurol 12: 207-216 (2013)
70. Maloney, B, Ge, YW, Petersen, RC, Hardy, J, Rogers, JT, Perez-Tur, J, Lahiri, DK. Functional characterization of three singlenucleotidepolymorphisms present in the human APOE promotersequence: Differential effects in neuronal cells and on DNA-proteininterations. Am J Med Genet B Neuropsychiatr Genet 153B: 185-201 (2010).